Project Grant R35GM164052
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded $420,981 to the University of California, Los Angeles on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support directed evolution of biocatalysts for asymmetric hydrogen atom transfer reactions. This five-year project, extending through February 28, 2031, will deliver engineered enzymatic catalysts capable of performing metal-hydride-mediated...
- Federal Project Grant Award Summary Under this Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859), the University of California, Los Angeles (UCLA) will develop efficient algorithms for searching and identifying known and novel small molecules in complex biological samples through mass spectrometry analysis. The award of $433,125 over five years (September 1, 2025 through August 31, 2030) supports...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded University of California, Los Angeles $150,104 under the Biomedical Research and Research Training program (CFDA 93.859) for a Project Grant beginning March 1, 2026, and concluding August 31, 2028. The research initiative, titled "Data-Science Guided Study and Design of Phosphoranyl Radical-Mediated Reactions," applies machine learning and data science methodologies to advance synthetic...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded Boston College $641,700 through the Biomedical Research and Research Training program (CFDA 93.859) on August 1, 2026, for a five-year project extending through March 31, 2031. The award supports the development of advanced chemical-proteomic tools and platforms to investigate cysteine modifications and their role in protein regulation. The research will generate novel chemical probes and...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), awarded a $420,984 Project Grant to the University of California, Los Angeles (UCLA) effective August 1, 2025, with a completion date of July 31, 2030. This award supports the development of statistical methods and analytical approaches to interpret deep mutational scanning (DMS) data, a high-throughput technology used to...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded $1.453 million to The Regents of the University of California, San Francisco under the Biomedical Research and Research Training program (CFDA 93.859) on September 5, 2025, with a completion date of May 31, 2030. This Project Grant supports fundamental research to bridge the gap between structural prediction models and experimental reality in structural biology. The principal investigator...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded $150,932 to the University of California, Los Angeles under the Biomedical Research and Research Training program (CFDA 93.859) for a two-year project running from September 1, 2025, through August 31, 2027. The award funds research into the design of phosphoranyl radical α-scission reactions enabled by photoredox catalysis and 1,5-hydrogen atom transfer mechanisms. This work aims to develop...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded University of California, Los Angeles $433,125 through the Biomedical Research and Research Training program (CFDA 93.859) beginning April 1, 2026, with completion scheduled for February 28, 2031. This Project Grant supports the development and refinement of an imaging-based molecular recording technology designed to reconstruct the signaling history of individual cells. The research expands...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded $124,767 to The Regents of the University of California, San Francisco under the Biomedical Research and Research Training program (CFDA 93.859) on May 1, 2026, with a completion date of April 30, 2028. This Project Grant supports de novo protein design research focused on engineering proteins that bind small molecules and catalyze chemical reactions. The funded work builds on the investigator's...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) awarded UC San Diego a $369,347 Project Grant beginning July 1, 2026, and extending through June 30, 2031, to conduct high-resolution structural analysis of megasynthases using cryo-electron microscopy (cryo-EM). The primary deliverables include development and application of molecular tools and probes to enable structural...
The National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) awarded $406,432 to the University of California, Los Angeles effective August 1, 2026, through April 30, 2031. This project grant supports the development and application of chemoproteomic technologies to identify functional and redox-sensitive cysteine residues in proteins. The research program delivers mass spectrometry-based methods to capture cysteine sites that may serve as targets for covalent drug development, with emphasis on improving sample throughput and enabling cost-effective redox proteomics analysis. The award supports three primary research deliverables: (1) enhanced chemoproteomic coverage through integration of long-read sequencing to enable proteoform-centric screening of protein splice variants; (2) subcellular redox proteomics platforms to pinpoint cysteines regulating protein localization and identify functionally relevant residues; and (3) combined cysteine chemoproteomic platforms with high-content imaging and atropisomeric electrophile libraries to determine cysteine drivers of stress granules. These technologies are designed to generate broadly applicable tools that facilitate discovery of therapeutically relevant cysteine residues and advance covalent drug development capabilities.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $406.4k | 7/10/26 |